Search

Your search keyword '"Edmondson, Richard"' showing total 514 results
Start Over Author "Edmondson, Richard"
514 results on '"Edmondson, Richard"'

2. British Gynaecological Cancer Society (BGCS) ovarian, tubal and primary peritoneal cancer guidelines: Recommendations for practice update 2024

Author

Moss, Esther, Taylor, Alexandra, Andreou, Adrian, Ang, Christine, Arora, Rupali, Attygalle, Ayoma, Banerjee, Susana, Bowen, Rebecca, Buckley, Lynn, Burbos, Nikos, Coleridge, Sarah, Edmondson, Richard, El-Bahrawy, Mona, Fotopoulou, Christina, Frost, Jonathan, Ganesan, Raji, George, Angela, Hanna, Louise, Kaur, Baljeet, Manchanda, Ranjit, Maxwell, Hillary, Michael, Agnieszka, Miles, Tracey, Newton, Claire, Nicum, Shibani, Ratnavelu, Nithya, Ryan, Neil, Sundar, Sudha, Vroobel, Katherine, Walther, Axel, Wong, Jason, and Morrison, Jo

Published
2024
Full Text
View/download PDF

3. The DNA damage response in advanced ovarian cancer: functional analysis combined with machine learning identifies signatures that correlate with chemotherapy sensitivity and patient outcome

Author

Walker, Thomas D. J., Faraahi, Zahra F., Price, Marcus J., Hawarden, Amy, Waddell, Caitlin A., Russell, Bryn, Jones, Dominique M., McCormick, Aiste, Gavrielides, N., Tyagi, S., Woodhouse, Laura C., Whalley, Bethany, Roberts, Connor, Crosbie, Emma J., and Edmondson, Richard J.

Published
2023
Full Text
View/download PDF

6. Human Spermbots for Cancer-Relevant Drug Delivery

Author

Xu, Haifeng, Medina-Sanchez, Mariana, Brison, Daniel R., Edmondson, Richard J., Taylor, Stephen S., Nelson, Louisa, Zeng, Kang, Bagley, Steven, Ribeiro, Carla, Restrepo, Lina P., Lucena, Elkin, Schmidt, Christine K., and Schmidt, Oliver G.

Subjects
Quantitative Biology - Cell Behavior
Abstract

Cellular micromotors are attractive for locally delivering high concentrations of drug and targeting hard-to-reach disease sites such as cervical cancer and early ovarian cancer lesions by non-invasive means. Spermatozoa are highly efficient micromotors perfectly adapted to traveling up the female reproductive system. Indeed, bovine sperm-based micromotors have recently been reported as a potential candidate for the drug delivery toward gynecological cancers of clinical unmet need. However, due to major differences in the molecular make-up of bovine and human sperm, a key translational bottleneck for bringing this technology closer to the clinic is to transfer this concept to human sperm. Here, we successfully load human sperm with a chemotherapeutic drug and perform treatment of relevant 3D cervical cancer and patient-representative 3D ovarian cancer cell cultures, resulting in strong anti-cancer effects. Additionally, we show the subcellular localization of the chemotherapeutic drug within human sperm heads and assess drug effects on sperm motility and viability over time. Finally, we demonstrate guidance and release of human drug-loaded sperm onto cancer cell cultures by using streamlined microcap designs capable of simultaneously carrying multiple human sperm towards controlled drug dosing by transporting known numbers of sperm loaded with defined amounts of chemotherapeutic drug.

Published
2019

8. p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

Author

Vermij, Lisa, Léon-Castillo, Alicia, Singh, Naveena, Powell, Melanie E., Edmondson, Richard J., Genestie, Catherine, Khaw, Pearly, Pyman, Jan, McLachlin, C. Meg, Ghatage, Prafull, de Boer, Stephanie M., Nijman, Hans W., Smit, Vincent T. H. B. M., Crosbie, Emma J., Leary, Alexandra, Creutzberg, Carien L., Horeweg, Nanda, and Bosse, Tjalling

Published
2022
Full Text
View/download PDF

11. Patient and clinician priorities for information on treatment outcomes for advanced ovarian cancer: a Delphi exercise.

Author

Baxter, Kathryn, Agnew, Heather, Morgan, Jennie, Holland, Cathrine, Flynn, Darren, and Edmondson, Richard

Subjects
PROGRESSION-free survival, CANCER patients, LITERATURE reviews, PATIENT preferences, PREFERRED stocks, OVARIAN cancer
Abstract

Objective: Patients with advanced ovarian cancer face a range of treatment options, and there is unwarranted variation in treatment decision-making between UK providers. Decision support tools that produce data on treatment outcomes as a function of individual patient characteristics, would help both patients and clinicians to make informed, preference- and values-based choices. However, data on treatment outcomes to include in such tools are lacking. Methods: Following a literature review, a questionnaire was designed for use in a Delphi process to establish which treatment outcomes are important to both patients and clinicians in decision-making for treatment for advanced ovarian cancer. Patient and clinician panels were established. Results: Following 2 Delphi rounds, consensus was achieved for 7/11 items in the patient panel and 8/11 items in the clinician panel. Consensus across both panels was achieved for inclusion of both overall survival and progression free survival as important items in the decision-making process, although there remained differences of opinion as to whether these should be presented as relative or absolute values. Conclusion: Information needs for treatment decision-making in ovarian cancer differ between and within patient and clinician groups. Whilst overall survival and progression free survival are universally accepted as important data items, decision support tools will need to be nuanced to allow presentation of a range of outcomes and associated probabilities, and in a range of formats, that can be tailored to the preferences of clinician and patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study

Author

Lakhiani, Aarti, primary, Cummins, Carole, additional, Kumar, Satyam, additional, Long, Joanna, additional, Arora, Vivek, additional, Balega, Janos, additional, Broadhead, Tim, additional, Duncan, Timothy, additional, Edmondson, Richard, additional, Fotopoulou, Christina, additional, Glasspool, Rosalind, additional, Kolomainen, Desiree, additional, Manchanda, Ranjit, additional, McNally, Orla, additional, Morrison, Jo, additional, Mukhopadhyay, Asima, additional, Naik, Raj, additional, Wood, Nick, additional, and Sundar, Sudha, additional

Published
2023
Full Text
View/download PDF

16. Mainstreaming germline BRCA1/2 testing in non-mucinous epithelial ovarian cancer in the North West of England

Author

Flaum, Nicola, Morgan, Robert D., Burghel, George J., Bulman, Michael, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire L., Badea, Doina, Moon, Sarah, Hogg, Martin, Hadjiyiannakis, Dennis, Clancy, Tara, Schlecht, Helene, Woodward, Emma R., Crosbie, Emma J., Edmondson, Richard J., Wallace, Andrew J., Jayson, Gordon C., Lalloo, Fiona I., Harkness, Elaine F., and Evans, D. Gareth R.

Published
2020
Full Text
View/download PDF

17. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer

Author

Bowtell, David D, Böhm, Steffen, Ahmed, Ahmed A, Aspuria, Paul-Joseph, Bast, Robert C, Beral, Valerie, Berek, Jonathan S, Birrer, Michael J, Blagden, Sarah, Bookman, Michael A, Brenton, James D, Chiappinelli, Katherine B, Martins, Filipe Correia, Coukos, George, Drapkin, Ronny, Edmondson, Richard, Fotopoulou, Christina, Gabra, Hani, Galon, Jérôme, Gourley, Charlie, Heong, Valerie, Huntsman, David G, Iwanicki, Marcin, Karlan, Beth Y, Kaye, Allyson, Lengyel, Ernst, Levine, Douglas A, Lu, Karen H, McNeish, Iain A, Menon, Usha, Narod, Steven A, Nelson, Brad H, Nephew, Kenneth P, Pharoah, Paul, Powell, Daniel J, Ramos, Pilar, Romero, Iris L, Scott, Clare L, Sood, Anil K, Stronach, Euan A, and Balkwill, Frances R

Subjects
Cancer, Ovarian Cancer, Prevention, Rare Diseases, Good Health and Well Being, Cystadenocarcinoma, Serous, Female, Humans, Neoplasm Grading, Ovarian Neoplasms, Prognosis, Survival Rate, Medical and Health Sciences, Oncology & Carcinogenesis
Abstract

High-grade serous ovarian cancer (HGSOC) accounts for 70-80% of ovarian cancer deaths, and overall survival has not changed significantly for several decades. In this Opinion article, we outline a set of research priorities that we believe will reduce incidence and improve outcomes for women with this disease. This 'roadmap' for HGSOC was determined after extensive discussions at an Ovarian Cancer Action meeting in January 2015.

Published
2015

18. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: The PARAGON trial – ANZGOG 0903

Author

Mileshkin, Linda, Edmondson, Richard, O'Connell, Rachel L., Sjoquist, Katrin M., Andrews, John, Jyothirmayi, Rema, Beale, Philip, Bonaventura, Tony, Goh, Jeffrey, Hall, Marcia, Clamp, Andrew, Green, John, Lord, Rosemary, Amant, Frédéric, Alexander, Laura, Carty, Karen, Paul, James, Scurry, James, Millan, David, Nottley, Steven, and Friedlander, Michael

Published
2019
Full Text
View/download PDF

20. Refinement of high-risk endometrial cancer classification using DNA damage response biomarkers: a TransPORTEC initiative

Author

Auguste, Aurélie, Genestie, Catherine, De Bruyn, Marco, Adam, Julien, Le Formal, Audrey, Drusch, Françoise, Pautier, Patricia, Crosbie, Emma J., MacKay, Helen, Kitchener, Henry C., Powell, Melanie, Pollock, Pamela M., Mileshkin, Linda, Edmondson, Richard J., Nout, Remi, Nijman, Hans W., Creutzberg, Carien L., Bosse, Tjalling, and Leary, Alexandra

Published
2018
Full Text
View/download PDF

21. PR024/#394 Molecular profiling of P53 mutant endometrial cancer reveals distinct subgroups with opportunities for personalized therapeutic approaches

Author

Blanc-Durand, Felix, primary, Kramer, Claire JH, additional, Rouleau, Etienne, additional, Vasseur, Antoine, additional, Bosse, Tjalling, additional, Boer, Stephanie De, additional, Edmondson, Richard, additional, Powell, Melanie, additional, Crosbie, Emma, additional, Singh, Naveena, additional, Mcalpine, Jessica, additional, Mackay, Helen, additional, Pollock, Pamela, additional, Mileshkin, Linda, additional, Scott, Clare, additional, Lim, Yi Wan, additional, Lim, Siew Eng, additional, Ngoi, Natalie Yan Li, additional, Tan, David, additional, and Leary, Alexandra, additional

Published
2023
Full Text
View/download PDF

24. Supplementary Table S2. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

25. Supplementary Methodology 1 from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

26. Supplementary Figure S3. from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

27. Data from Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., primary, White, Daniel J., primary, Price, Marcus, primary, Burghel, George J., primary, Ryder, W. David J., primary, Mahmood, Reem D., primary, Murphy, Alexander D., primary, Hasan, Jurjees, primary, Mitchell, Claire L., primary, Salih, Zena, primary, Wheeler, Chelsey, primary, Buckley, Emma, primary, Truelove, Joanna, primary, King, Georgia, primary, Ainaoui, Yasmina, primary, Bhaskar, Sanjeev S., primary, Shaw, Joseph, primary, Evans, D. Gareth R., primary, Kilerci, Bedirhan, primary, Pearce, Simon P., primary, Brady, Gerard, primary, Dive, Caroline, primary, O'Connor, James P.B., primary, Wallace, Andrew J., primary, Rothwell, Dominic G., primary, Edmondson, Richard J., primary, and Jayson, Gordon C., primary

Published
2023
Full Text
View/download PDF

30. A living biobank of ovarian cancer ex vivo models reveals profound mitotic heterogeneity

Author

Nelson, Louisa, Tighe, Anthony, Golder, Anya, Littler, Samantha, Bakker, Bjorn, Moralli, Daniela, Murtuza Baker, Syed, Donaldson, Ian J., Spierings, Diana C. J., Wardenaar, René, Neale, Bethanie, Burghel, George J., Winter-Roach, Brett, Edmondson, Richard, Clamp, Andrew R., Jayson, Gordon C., Desai, Sudha, Green, Catherine M., Hayes, Andy, Foijer, Floris, Morgan, Robert D., and Taylor, Stephen S.

Published
2020
Full Text
View/download PDF

31. Analysis of Anxiety, Depression and Fear of Progression at 12 Months Post-Cytoreductive Surgery in the SOCQER-2 (Surgery in Ovarian Cancer—Quality of Life Evaluation Research) Prospective, International, Multicentre Study.

Author

Lakhiani, Aarti, Cummins, Carole, Kumar, Satyam, Long, Joanna, Arora, Vivek, Balega, Janos, Broadhead, Tim, Duncan, Timothy, Edmondson, Richard, Fotopoulou, Christina, Glasspool, Rosalind, Kolomainen, Desiree, Manchanda, Ranjit, McNally, Orla, Morrison, Jo, Mukhopadhyay, Asima, Naik, Raj, Wood, Nick, and Sundar, Sudha

Subjects
DISEASE progression, RESEARCH, CANCER patient psychology, OVARIAN tumors, FEAR, MENTAL health, ATTITUDES toward illness, PATIENTS' attitudes, TUMOR classification, TREATMENT effectiveness, MENTAL depression, QUALITY of life, POSTOPERATIVE period, DISEASE prevalence, QUESTIONNAIRES, DESCRIPTIVE statistics, ANXIETY, CYTOREDUCTIVE surgery, BODY mass index, LONGITUDINAL method
Abstract

Simple Summary: Anxiety, depression and fear of cancer progression are common psychological challenges faced by women with ovarian cancer. It can affect a person's well-being, treatment compliance and quality of life. In this study, we assessed how often and how severe these concerns are 12 months after surgical treatment and if there is any association with surgical, patient and tumour factors. A total of 141 patients with advanced ovarian cancer who did not have disease progression at 12 months post-surgery completed two questionnaires. We found that a significant proportion of patients undergoing surgery for ovarian cancer experience anxiety, depression and fear of progression. It was not possible to identify a group of patients who are more affected by anxiety, depression or fear of progression. It is essential for healthcare providers to be attentive to the emotional needs of all ovarian cancer patients and provide appropriate support to help them cope with these psychological concerns effectively. Patients with ovarian cancer (OC) often experience anxiety, depression and fear of progression (FOP); however, it is unclear whether surgical complexity has a role to play. We investigated the prevalence of anxiety, depression and FOP at 12 months post-cytoreductive surgery and investigated associations with surgical complexity, patient (age, ethnicity, performance status, BMI) and tumour (stage, disease load) factors. One hundred and forty-one patients with FIGO Stage III–IV OC, who did not have disease progression at 12 months post-surgery, completed the Hospital Anxiety and Depression Scale and FOP short-form questionnaire. Patients underwent surgery with low (40.4%), intermediate (31.2%) and high (28.4%) surgical complexity scores. At 12 months post-surgery, 99 of 141 (70%) patients with advanced OC undergoing surgery experienced clinically significant anxiety, 21 of 141 (14.9%) patients experienced moderate to severe depression and 37 of 140 (26.4%) experienced dysfunctional FOP. No associations were identified between the three different surgical complexity groups with regards to anxiety, depression or FOP scores. Unsurprisingly, given the natural history of the disease, most patients with OC suffer from anxiety, depression and fear of progression after completion of first-line cancer treatment. Surgical complexity at the time of surgery is not associated with a deleterious impact on anxiety, depression or FOP for patients with OC. Patients with OC experience a profound mental health impact and should be offered mental health support throughout their cancer journey. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

33. Copy number signatures and mutational processes in ovarian carcinoma

Author

Macintyre, Geoff, Goranova, Teodora E., De Silva, Dilrini, Ennis, Darren, Piskorz, Anna M., Eldridge, Matthew, Sie, Daoud, Lewsley, Liz-Anne, Hanif, Aishah, Wilson, Cheryl, Dowson, Suzanne, Glasspool, Rosalind M., Lockley, Michelle, Brockbank, Elly, Montes, Ana, Walther, Axel, Sundar, Sudha, Edmondson, Richard, Hall, Geoff D., Clamp, Andrew, Gourley, Charlie, Hall, Marcia, Fotopoulou, Christina, Gabra, Hani, Paul, James, Supernat, Anna, Millan, David, Hoyle, Aoisha, Bryson, Gareth, Nourse, Craig, Mincarelli, Laura, Sanchez, Luis Navarro, Ylstra, Bauke, Jimenez-Linan, Mercedes, Moore, Luiza, Hofmann, Oliver, Markowetz, Florian, McNeish, Iain A., and Brenton, James D.

Published
2018
Full Text
View/download PDF

35. Table S1 from PROgesterone Therapy for Endometrial Cancer Prevention in Obese Women (PROTEC) Trial: A Feasibility Study

Author

Derbyshire, Abigail E., primary, Allen, Jennifer L., primary, Gittins, Matthew, primary, Lakhiani, Bhavna, primary, Bolton, James, primary, Shaw, Joseph, primary, Pemberton, Philip W., primary, Needham, Michelle, primary, MacKintosh, Michelle L., primary, Edmondson, Richard J., primary, Kitchener, Henry C., primary, and Crosbie, Emma J., primary

Published
2023
Full Text
View/download PDF

37. Supplementary Data from Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors

Author

Mukhopadhyay, Asima, primary, Elattar, Ahmed, primary, Cerbinskaite, Aiste, primary, Wilkinson, Sarah J., primary, Drew, Yvette, primary, Kyle, Suzanne, primary, Los, Gerrit, primary, Hostomsky, Zdenek, primary, Edmondson, Richard J., primary, and Curtin, Nicola J., primary

Published
2023
Full Text
View/download PDF

38. Data from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Author

Mukhopadhyay, Asima, primary, Plummer, Elizabeth R., primary, Elattar, Ahmed, primary, Soohoo, San, primary, Uzir, Bisha, primary, Quinn, Jennifer E., primary, McCluggage, W. Glenn, primary, Maxwell, Perry, primary, Aneke, Harriet, primary, Curtin, Nicola J., primary, and Edmondson, Richard J., primary

Published
2023
Full Text
View/download PDF

39. Supplementary Figure 2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Author

Mukhopadhyay, Asima, primary, Plummer, Elizabeth R., primary, Elattar, Ahmed, primary, Soohoo, San, primary, Uzir, Bisha, primary, Quinn, Jennifer E., primary, McCluggage, W. Glenn, primary, Maxwell, Perry, primary, Aneke, Harriet, primary, Curtin, Nicola J., primary, and Edmondson, Richard J., primary

Published
2023
Full Text
View/download PDF

40. Supplementary Figure 1 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Author

Mukhopadhyay, Asima, primary, Plummer, Elizabeth R., primary, Elattar, Ahmed, primary, Soohoo, San, primary, Uzir, Bisha, primary, Quinn, Jennifer E., primary, McCluggage, W. Glenn, primary, Maxwell, Perry, primary, Aneke, Harriet, primary, Curtin, Nicola J., primary, and Edmondson, Richard J., primary

Published
2023
Full Text
View/download PDF

41. Supplementary Figure Legends 1-2 from Clinicopathological Features of Homologous Recombination–Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival

Author

Mukhopadhyay, Asima, primary, Plummer, Elizabeth R., primary, Elattar, Ahmed, primary, Soohoo, San, primary, Uzir, Bisha, primary, Quinn, Jennifer E., primary, McCluggage, W. Glenn, primary, Maxwell, Perry, primary, Aneke, Harriet, primary, Curtin, Nicola J., primary, and Edmondson, Richard J., primary

Published
2023
Full Text
View/download PDF

43. Working together to shape the endometrial cancer research agenda: The top ten unanswered research questions

Author

Wan, Y. Louise, Beverley-Stevenson, Rachel, Carlisle, Daloni, Clarke, Sinead, Edmondson, Richard J., Glover, Steve, Holland, Julie, Hughes, Carol, Kitchener, Henry C., Kitson, Sarah, Miles, Tracie, Morley, Richard, Morrison, Jo, Nelson, Linsey, Powell, Melanie, Sadler, Laura, Tomlinson, Anne, Tylko-Hill, Katharine, Whitcombe, Jo, and Crosbie, Emma J.

Published
2016
Full Text
View/download PDF

45. Predicting the likelihood of a BRCA1/2 pathogenic variant being somatic by testing only tumour DNA in non-mucinous high-grade epithelial ovarian cancer.

Author

Morgan, Robert D., Burghel, George J., Flaum, Nicola, Bulman, Michael, Smith, Philip, Clamp, Andrew R., Hasan, Jurjees, Mitchell, Claire, Salih, Zena, Woodward, Emma R., Lalloo, Fiona, Shaw, Joseph, Desai, Sudha, Crosbie, Emma J., Edmondson, Richard J., Schlecht, Helene, Wallace, Andrew J., Jayson, Gordon C., and Evans, Gareth R.

Subjects
BREAST, OVARIAN epithelial cancer, TUMORS, NUCLEOTIDE sequencing, CLINICAL trials, DNA
Published
2023
Full Text
View/download PDF

46. Multi-Maintenance Olaparib Therapy in Relapsed, Germline BRCA1/2-Mutant High-Grade Serous Ovarian Cancer (MOLTO): A Phase II Trial

Author

Morgan, Robert D., primary, Clamp, Andrew R., additional, White, Daniel J., additional, Price, Marcus, additional, Burghel, George J., additional, Ryder, W. David J., additional, Mahmood, Reem D., additional, Murphy, Alexander D., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Wheeler, Chelsey, additional, Buckley, Emma, additional, Truelove, Joanna, additional, King, Georgia, additional, Ainaoui, Yasmina, additional, Bhaskar, Sanjeev S., additional, Shaw, Joseph, additional, Evans, D. Gareth R., additional, Kilerci, Bedirhan, additional, Pearce, Simon P., additional, Brady, Gerard, additional, Dive, Caroline, additional, O'Connor, James P.B., additional, Wallace, Andrew J., additional, Rothwell, Dominic G., additional, Edmondson, Richard J., additional, and Jayson, Gordon C., additional

Published
2023
Full Text
View/download PDF

47. Is Reflex Germline BRCA1/2 Testing Necessary in Women Diagnosed with Non-Mucinous High-Grade Epithelial Ovarian Cancer Aged 80 Years or Older?

Author

Morgan, Robert D., primary, Burghel, George J., additional, Flaum, Nicola, additional, Bulman, Michael, additional, Smith, Philip, additional, Clamp, Andrew R., additional, Hasan, Jurjees, additional, Mitchell, Claire L., additional, Salih, Zena, additional, Woodward, Emma R., additional, Lalloo, Fiona, additional, Crosbie, Emma J., additional, Edmondson, Richard J., additional, Schlecht, Helene, additional, Jayson, Gordon C., additional, and Evans, D. Gareth R., additional

Published
2023
Full Text
View/download PDF

48. British Gynaecological Cancer Society Recommendations for Evidence Based, Population Data Derived Quality Performance Indicators for Ovarian Cancer

Author

Sundar, Sudha, primary, Nordin, Andy, additional, Morrison, Jo, additional, Wood, Nick, additional, Ghaem-Maghami, Sadaf, additional, Nieto, Jo, additional, Phillips, Andrew, additional, Butler, John, additional, Burton, Kevin, additional, Gornall, Rob, additional, Dobbs, Stephen, additional, Glasspool, Rosalind, additional, Peevor, Richard, additional, Ledermann, Jonathan, additional, McNeish, Iain, additional, Ratnavelu, Nithya, additional, Duncan, Tim, additional, Frost, Jonathan, additional, Lim, Kenneth, additional, Michael, Agnieszka, additional, Brockbank, Elly, additional, Gajjar, Ketankumar, additional, Taylor, Alexandra, additional, Bowen, Rebecca, additional, Andreou, Adrian, additional, Ganesan, Raji, additional, Nicum, Shibani, additional, Edmondson, Richard, additional, Clayton, Richard, additional, Balega, Janos, additional, Rolland, Phil, additional, Maxwell, Hilary, additional, and Fotopoulou, Christina, additional

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results